Figure 5 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium

Impact of radiotherapy. A, Patient progressing on nivolumab received reirradiation, following which further progression prompted the addition of ipilimumab. This was followed by radiologic flare, and continued treatment with supportive care led to delayed response. B, Impact of reirradiation on survival. C, Impact of additional reirradiation (RT) in patients who received nivolumab and ipilimumab. D, Relative contribution of the radiation-induced indel signature (ID8) in RRD-HGG and controls from the GLASS cohort (Methods). E, Paired analysis of the relative contribution of ID8 before (at diagnosis) and after the second progression (post primary radiation, and then immunotherapy at first progression) in five patients.